First Affiliated Hospital Of Guangxi Medical University
Clinical trials sponsored by First Affiliated Hospital Of Guangxi Medical University, explained in plain language.
-
New combo therapy trial aims to fight tough sarcomas
Disease control Not yet recruitingThis study is testing a new combination treatment for people with advanced soft tissue sarcoma that cannot be removed by surgery or has spread. The treatment mixes a specialized form of radiation with several immunotherapy drugs. Researchers want to see if this approach is safe a…
Phase: PHASE2 • Sponsor: First Affiliated Hospital of Guangxi Medical University • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New hope for kids with leukemia: early trial tests cutting-edge CAR-T treatment
Disease control Not yet recruitingThis is an early-stage study to test the safety and see if a new type of CAR-T cell therapy might help children whose acute myeloid leukemia has come back or hasn't responded to other treatments. Doctors will collect a child's own immune cells, modify them in a lab to target a pr…
Phase: EARLY_PHASE1 • Sponsor: First Affiliated Hospital of Guangxi Medical University • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Spray from stem cells could shield cancer patients from agonizing mouth sores
Disease control Not yet recruitingThis study is testing a new spray made from particles released by stem cells to see if it can prevent and treat severe mouth sores in people receiving radiation for head and neck cancer. It will involve 200 patients, with half receiving the spray and half receiving standard care.…
Phase: PHASE2 • Sponsor: First Affiliated Hospital of Guangxi Medical University • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New hope for Wake-Up strokes: major trial tests Game-Changing treatment
Disease control Not yet recruitingThis study is testing whether a clot-busting drug called tenecteplase can help people who have a stroke but don't know when it started, such as when they wake up with symptoms. About 352 participants will be randomly assigned to receive either the drug plus standard care or stand…
Phase: PHASE3 • Sponsor: First Affiliated Hospital of Guangxi Medical University • Aim: Disease control
Last updated Mar 27, 2026 12:37 UTC